Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Variants & evidence
70 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRG1 Expression1 | ||||||||
| Lapatinib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID776In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified… (full text at CIViC) PMID 21840482 · Wilson et al., 2011 · Open in CIViC | civic |
| PIK3CA Amplification2 | ||||||||
| Aspirin + Ibuprofen + SulindacSubstitutes | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7186In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation,… (full text at CIViC) PMID 30683736 · Hedberg et al., 2019 · Open in CIViC | civic |
| Taselisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID1464The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PIK3CA E542K1 | ||||||||
| Apitolisib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1549Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirm… (full text at CIViC) PMID 26787751 · Dolly et al., 2016 · Open in CIViC | civic |
| PIK3CA H1047R1 | ||||||||
| Taselisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1465The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib conc… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PIK3CA Mutation2 | ||||||||
| Aspirin + Celecoxib + SulindacSubstitutes | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7185In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation,… (full text at CIViC) PMID 30683736 · Hedberg et al., 2019 · Open in CIViC | civic |
| Radiation Therapy + TaselisibCombination | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1490A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensiti… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PTEN Mutation1 | ||||||||
| Taselisib | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | 3 | accepted | EID1467In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably … (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC | civic |
| PTPRT Promoter Hypermethylation1 | ||||||||
| JSI-124 + StatticSubstitutes | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID817PTPRT promoter hypermethylation was associated with increased sensitivity to STAT3 inhibition in this preclinical study in HNSCC. The authors found that PTPRT promoter methylation and sensitivity to S… (full text at CIViC) PMID 25982282 · Peyser et al., 2016 · Open in CIViC | civic |
| SMAD4 Underexpression1 | ||||||||
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | 3 | accepted | EID720In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab. PMID 26046389 · Cheng et al., 2015 · Open in CIViC | civic |
| TGFA EXPRESSION1 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID785Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC) PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC | civic |
| High2 | ||||||||
| Durvalumab | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID12850This retrospective analysis of the Phase 3 EAGLE trial (NCT02369874) evaluated tissue tumor mutational burden (tTMB) and blood TMB (bTMB) as predictive biomarkers in platinum-refractory recurrent or m… (full text at CIViC) PMID 36806911 · Wildsmith et al., 2023 · Open in CIViC | civic |
| PD1 Inhibitor | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID13241This observational cohort study assessed the association between total mutational burden (TMB) and the efficacy of anti-PD-1/L1 therapy in head and neck squamous cell carcinoma. Using large comprehens… (full text at CIViC) PMID 29467336 · Hanna et al., 2018 · Open in CIViC | civic |
| TP53 Deleterious Mutation1 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID517In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those witho… (full text at CIViC) PMID 22090360 · Skinner et al., 2012 · Open in CIViC | civic |
| TP53 DNA Binding Domain Mutation1 | ||||||||
| (prognostic) | Oral Cavity Squamous Cell CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID641Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC) PMID 12509970 · Yamazaki et al., 2003 · Open in CIViC | civic |
| TP53 Mutation3 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Does Not Support Poor Outcome | 4 | accepted | EID523Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with … (full text at CIViC) PMID 11325447 · Alsner et al., 2001 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID524Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of l… (full text at CIViC) PMID 11325447 · Alsner et al., 2001 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Does Not Support | ||||
| TP53 Truncating Mutation2 | ||||||||
| (prognostic) | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID525In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients. PMID 21467160 · Lindenbergh-van der Plas et al., 2011 · Open in CIViC | civic |
| 〃 | Head and Neck Squamous Cell Carcinoma | Prognostic | B | Does Not Support Poor Outcome | 4 | accepted | EID526In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate ana… (full text at CIViC) PMID 21467160 · Lindenbergh-van der Plas et al., 2011 · Open in CIViC | civic |
Data updated 14 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| accepted |
EID518Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutati… (full text at CIViC) PMID 8901856 · Koch et al., 1996 · Open in CIViC |
| civic |